The Experts below are selected from a list of 9396 Experts worldwide ranked by ideXlab platform

Tamara Minko - One of the best experts on this subject based on the ideXlab platform.

  • intratracheal versus intravenous Liposomal Delivery of sirna antisense oligonucleotides and anticancer drug
    Pharmaceutical Research, 2009
    Co-Authors: Olga B Garbuzenko, Maha Saad, Seema Betigeri, Min Zhang, Alexandre A Vetcher, Viatcheslav A Soldatenkov, David Reimer, Vitaly P Pozharov, Tamara Minko
    Abstract:

    Purpose To compare systemic intravenous and local intratracheal Delivery of doxorubicin (DOX), antisense oligonucleotides (ASO) and small interfering RNA (siRNA).

  • intratracheal versus intravenous Liposomal Delivery of sirna antisense oligonucleotides and anticancer drug
    Pharmaceutical Research, 2009
    Co-Authors: Olga B Garbuzenko, Maha Saad, Seema Betigeri, Min Zhang, Alexandre A Vetcher, Viatcheslav A Soldatenkov, David Reimer, Vitaly P Pozharov, Tamara Minko
    Abstract:

    To compare systemic intravenous and local intratracheal Delivery of doxorubicin (DOX), antisense oligonucleotides (ASO) and small interfering RNA (siRNA). “Neutral” and cationic liposomes were used to deliver DOX, ASO, and siRNA. Liposomes were characterized by dynamic light scattering, zeta-potential, and atomic force microscopy. Cellular internalization of DOX, ASO and siRNA was studied by confocal microscopy on human lung carcinoma cells. In vivo experiments were carried out on nude mice with an orthotopic model of human lung cancer. Liposomes provided for an efficient intracellular Delivery of DOX, ASO, and siRNA in vitro. Intratracheal Delivery of both types of liposomes in vivo led to higher peak concentrations and much longer retention of liposomes, DOX, ASO and siRNA in the lungs when compared with systemic administration. It was found that local intratracheal treatment of lung cancer with Liposomal DOX was more efficient when compared with free and Liposomal DOX delivered intravenously. The present study outlined the clear advantages of local intratracheal Delivery of Liposomal drugs for the treatment of lung cancer when compared with systemic administration of the same drug.

  • in vitro and in vivo intracellular Liposomal Delivery of antisense oligonucleotides and anticancer drug
    Journal of Controlled Release, 2006
    Co-Authors: Refika I Pakunlu, Maha Saad, Yang Wang, Jayant Khandare, Valentin Starovoytov, Tamara Minko
    Abstract:

    The specific aims of this investigation were (1) to show that conventional and PEGylated liposomes can penetrate cancer cells in vitro and in vivo; (2) to demonstrate that liposomes can be successfully used both for cytoplasmic and nuclear Delivery of therapeutics, including anticancer drugs and antisense oligonucleotides; (3) to examine the specific activity of anticancer drugs and nucleotides delivered inside tumor cells by PEGylated liposomes; and (4) to confirm that simultaneous inhibition of pump and nonpump cellular resistance by Liposomal ASO can substantially enhance the antitumor activity of traditional well established anticancer drugs in mice bearing xenografts of human multidrug resistant ovarian carcinoma. Experimental results show that PEGylated liposomes are capable of penetrating directly into tumor cells after systemic administration in vivo and do successfully provide cytoplasmic and nuclear Delivery of encapsulated anticancer drug (doxorubicin, DOX) and antisense oligonucleotides (ASO). Encapsulation of DOX and ASO into liposomes substantially increased their specific activity. Simultaneous suppression of pump and nonpump resistance dramatically enhanced the ability of DOX for inducing apoptosis leading to higher in vitro cytotoxicity and in vivo antitumor activity.

Viatcheslav A Soldatenkov - One of the best experts on this subject based on the ideXlab platform.

  • intratracheal versus intravenous Liposomal Delivery of sirna antisense oligonucleotides and anticancer drug
    Pharmaceutical Research, 2009
    Co-Authors: Olga B Garbuzenko, Maha Saad, Seema Betigeri, Min Zhang, Alexandre A Vetcher, Viatcheslav A Soldatenkov, David Reimer, Vitaly P Pozharov, Tamara Minko
    Abstract:

    Purpose To compare systemic intravenous and local intratracheal Delivery of doxorubicin (DOX), antisense oligonucleotides (ASO) and small interfering RNA (siRNA).

  • intratracheal versus intravenous Liposomal Delivery of sirna antisense oligonucleotides and anticancer drug
    Pharmaceutical Research, 2009
    Co-Authors: Olga B Garbuzenko, Maha Saad, Seema Betigeri, Min Zhang, Alexandre A Vetcher, Viatcheslav A Soldatenkov, David Reimer, Vitaly P Pozharov, Tamara Minko
    Abstract:

    To compare systemic intravenous and local intratracheal Delivery of doxorubicin (DOX), antisense oligonucleotides (ASO) and small interfering RNA (siRNA). “Neutral” and cationic liposomes were used to deliver DOX, ASO, and siRNA. Liposomes were characterized by dynamic light scattering, zeta-potential, and atomic force microscopy. Cellular internalization of DOX, ASO and siRNA was studied by confocal microscopy on human lung carcinoma cells. In vivo experiments were carried out on nude mice with an orthotopic model of human lung cancer. Liposomes provided for an efficient intracellular Delivery of DOX, ASO, and siRNA in vitro. Intratracheal Delivery of both types of liposomes in vivo led to higher peak concentrations and much longer retention of liposomes, DOX, ASO and siRNA in the lungs when compared with systemic administration. It was found that local intratracheal treatment of lung cancer with Liposomal DOX was more efficient when compared with free and Liposomal DOX delivered intravenously. The present study outlined the clear advantages of local intratracheal Delivery of Liposomal drugs for the treatment of lung cancer when compared with systemic administration of the same drug.

Maha Saad - One of the best experts on this subject based on the ideXlab platform.

  • intratracheal versus intravenous Liposomal Delivery of sirna antisense oligonucleotides and anticancer drug
    Pharmaceutical Research, 2009
    Co-Authors: Olga B Garbuzenko, Maha Saad, Seema Betigeri, Min Zhang, Alexandre A Vetcher, Viatcheslav A Soldatenkov, David Reimer, Vitaly P Pozharov, Tamara Minko
    Abstract:

    Purpose To compare systemic intravenous and local intratracheal Delivery of doxorubicin (DOX), antisense oligonucleotides (ASO) and small interfering RNA (siRNA).

  • intratracheal versus intravenous Liposomal Delivery of sirna antisense oligonucleotides and anticancer drug
    Pharmaceutical Research, 2009
    Co-Authors: Olga B Garbuzenko, Maha Saad, Seema Betigeri, Min Zhang, Alexandre A Vetcher, Viatcheslav A Soldatenkov, David Reimer, Vitaly P Pozharov, Tamara Minko
    Abstract:

    To compare systemic intravenous and local intratracheal Delivery of doxorubicin (DOX), antisense oligonucleotides (ASO) and small interfering RNA (siRNA). “Neutral” and cationic liposomes were used to deliver DOX, ASO, and siRNA. Liposomes were characterized by dynamic light scattering, zeta-potential, and atomic force microscopy. Cellular internalization of DOX, ASO and siRNA was studied by confocal microscopy on human lung carcinoma cells. In vivo experiments were carried out on nude mice with an orthotopic model of human lung cancer. Liposomes provided for an efficient intracellular Delivery of DOX, ASO, and siRNA in vitro. Intratracheal Delivery of both types of liposomes in vivo led to higher peak concentrations and much longer retention of liposomes, DOX, ASO and siRNA in the lungs when compared with systemic administration. It was found that local intratracheal treatment of lung cancer with Liposomal DOX was more efficient when compared with free and Liposomal DOX delivered intravenously. The present study outlined the clear advantages of local intratracheal Delivery of Liposomal drugs for the treatment of lung cancer when compared with systemic administration of the same drug.

  • in vitro and in vivo intracellular Liposomal Delivery of antisense oligonucleotides and anticancer drug
    Journal of Controlled Release, 2006
    Co-Authors: Refika I Pakunlu, Maha Saad, Yang Wang, Jayant Khandare, Valentin Starovoytov, Tamara Minko
    Abstract:

    The specific aims of this investigation were (1) to show that conventional and PEGylated liposomes can penetrate cancer cells in vitro and in vivo; (2) to demonstrate that liposomes can be successfully used both for cytoplasmic and nuclear Delivery of therapeutics, including anticancer drugs and antisense oligonucleotides; (3) to examine the specific activity of anticancer drugs and nucleotides delivered inside tumor cells by PEGylated liposomes; and (4) to confirm that simultaneous inhibition of pump and nonpump cellular resistance by Liposomal ASO can substantially enhance the antitumor activity of traditional well established anticancer drugs in mice bearing xenografts of human multidrug resistant ovarian carcinoma. Experimental results show that PEGylated liposomes are capable of penetrating directly into tumor cells after systemic administration in vivo and do successfully provide cytoplasmic and nuclear Delivery of encapsulated anticancer drug (doxorubicin, DOX) and antisense oligonucleotides (ASO). Encapsulation of DOX and ASO into liposomes substantially increased their specific activity. Simultaneous suppression of pump and nonpump resistance dramatically enhanced the ability of DOX for inducing apoptosis leading to higher in vitro cytotoxicity and in vivo antitumor activity.

Olga B Garbuzenko - One of the best experts on this subject based on the ideXlab platform.

  • intratracheal versus intravenous Liposomal Delivery of sirna antisense oligonucleotides and anticancer drug
    Pharmaceutical Research, 2009
    Co-Authors: Olga B Garbuzenko, Maha Saad, Seema Betigeri, Min Zhang, Alexandre A Vetcher, Viatcheslav A Soldatenkov, David Reimer, Vitaly P Pozharov, Tamara Minko
    Abstract:

    Purpose To compare systemic intravenous and local intratracheal Delivery of doxorubicin (DOX), antisense oligonucleotides (ASO) and small interfering RNA (siRNA).

  • intratracheal versus intravenous Liposomal Delivery of sirna antisense oligonucleotides and anticancer drug
    Pharmaceutical Research, 2009
    Co-Authors: Olga B Garbuzenko, Maha Saad, Seema Betigeri, Min Zhang, Alexandre A Vetcher, Viatcheslav A Soldatenkov, David Reimer, Vitaly P Pozharov, Tamara Minko
    Abstract:

    To compare systemic intravenous and local intratracheal Delivery of doxorubicin (DOX), antisense oligonucleotides (ASO) and small interfering RNA (siRNA). “Neutral” and cationic liposomes were used to deliver DOX, ASO, and siRNA. Liposomes were characterized by dynamic light scattering, zeta-potential, and atomic force microscopy. Cellular internalization of DOX, ASO and siRNA was studied by confocal microscopy on human lung carcinoma cells. In vivo experiments were carried out on nude mice with an orthotopic model of human lung cancer. Liposomes provided for an efficient intracellular Delivery of DOX, ASO, and siRNA in vitro. Intratracheal Delivery of both types of liposomes in vivo led to higher peak concentrations and much longer retention of liposomes, DOX, ASO and siRNA in the lungs when compared with systemic administration. It was found that local intratracheal treatment of lung cancer with Liposomal DOX was more efficient when compared with free and Liposomal DOX delivered intravenously. The present study outlined the clear advantages of local intratracheal Delivery of Liposomal drugs for the treatment of lung cancer when compared with systemic administration of the same drug.

Huan Meng - One of the best experts on this subject based on the ideXlab platform.

  • breast cancer chemo immunotherapy through Liposomal Delivery of an immunogenic cell death stimulus plus interference in the ido 1 pathway
    ACS Nano, 2018
    Co-Authors: Jianqin Lu, Yupei Liao, Xiang Wang, Ayman Ahmed, Wen Jiang, Ying Ji, Huan Meng
    Abstract:

    Immunotherapy provides the best approach to reduce the high mortality of metastatic breast cancer (BC). We demonstrate a chemo-immunotherapy approach, which utilizes a Liposomal carrier to simultaneously trigger immunogenic cell death (ICD) as well as interfere in the regionally overexpressed immunosuppressive effect of indoleamine 2,3-dioxygenase (IDO-1) at the BC tumor site. The liposome was constructed by self-assembly of a phospholipid-conjugated prodrug, indoximod (IND), which inhibits the IDO-1 pathway, followed by the remote loading of the ICD-inducing chemo drug, doxorubicin (DOX). Intravenous injection of the encapsulated two-drug combination dramatically improved the pharmacokinetics and tumor drug concentrations of DOX and IND in an orthotopic 4T1 tumor model in syngeneic mice. Delivery of a threshold ICD stimulus resulted in the uptake of dying BC cells by dendritic cells, tumor antigen presentation and the activation/recruitment of naive T-cells. The subsequent activation of perforin- and IF...

  • breast cancer chemo immunotherapy through Liposomal Delivery of an immunogenic cell death stimulus plus interference in the ido 1 pathway
    ACS Nano, 2018
    Co-Authors: Xiangsheng Liu, Yupei Liao, Xiang Wang, Ayman Ahmed, Wen Jiang, Huan Meng, Andre E Nel
    Abstract:

    Immunotherapy provides the best approach to reduce the high mortality of metastatic breast cancer (BC). We demonstrate a chemo-immunotherapy approach, which utilizes a Liposomal carrier to simultaneously trigger immunogenic cell death (ICD) as well as interfere in the regionally overexpressed immunosuppressive effect of indoleamine 2,3-dioxygenase (IDO-1) at the BC tumor site. The liposome was constructed by self-assembly of a phospholipid-conjugated prodrug, indoximod (IND), which inhibits the IDO-1 pathway, followed by the remote loading of the ICD-inducing chemo drug, doxorubicin (DOX). Intravenous injection of the encapsulated two-drug combination dramatically improved the pharmacokinetics and tumor drug concentrations of DOX and IND in an orthotopic 4T1 tumor model in syngeneic mice. Delivery of a threshold ICD stimulus resulted in the uptake of dying BC cells by dendritic cells, tumor antigen presentation and the activation/recruitment of naive T-cells. The subsequent activation of perforin- and IFN-γ releasing cytotoxic T-cells induced robust tumor cell killing at the primary as well as metastatic tumor sites. Immune phenotyping of the tumor tissues confirmed the recruitment of CD8+ cytotoxic T lymphocytes (CTLs), disappearance of Tregs, and an increase in CD8+/FOXP3+ T-cell ratios. Not only does the DOX/IND-Liposome provide a synergistic antitumor response that is superior to a DOX-only liposome, but it also demonstrated that the carrier could be effectively combined with PD-1 blocking antibodies to eradicate lung metastases. All considered, an innovative nano-enabled approach has been established to allow deliberate use of ICD to switch an immune deplete to an immune replete BC microenvironment, allowing further boosting of the response by coadministered IDO inhibitors or immune checkpoint blocking antibodies.